Results 31 to 40 of about 61,480 (319)
Three new shRNA expression vectors targeting the CYP3A4 coding sequence to inhibit its expression
Acta Pharmaceutica Sinica B, 2014 RNA interference (RNAi) is useful for selective gene silencing. Cytochrome P450 3A4 (CYP3A4), which metabolizes approximately 50% of drugs in clinical use, plays an important role in drug metabolism. In this study, we aimed to develop a short hairpin RNA
Siyun Xu +6 more
doaj +1 more source
Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism
Pharmaceutical Biology, 2020 Context Hydroxycamptothecin (HCPT) has antitumor activity in various cancers, but its poor bioavailability and efflux limit its clinical application. Verapamil has been demonstrated to improve the bioavailability of many drugs.
Hua Xing +6 more
doaj +1 more source
Journal of Pharmacological Sciences, 2004 A relatively large amount of human liver tissue was required to determine the exact activity of human hepatic CYP3A. Although, the quantity of available human liver tissue samples is limited.
Minoru Watanabe +6 more
doaj +1 more source
Scientific Reports, 2019 Lenvatinib is a substrate of cytochrome P450 (CYP) 3A and ATP-binding cassette (ABC) transporters. In this study, we aimed to evaluate how CYP3A4/5 and ABC transporter polymorphisms affected the mean steady-state dose-adjusted plasma trough ...
T. Ozeki +6 more
semanticscholar +1 more source
CYP3A4 and CYP3A5genotyping by Pyrosequencing [PDF]
BMC Medical Genetics, 2005 Human cytochrome P450 3A enzymes, particularly CYP3A4 and CYP3A5, play an important role in drug metabolism. CYP3A expression exhibits substantial interindividual variation, much of which may result from genetic variation. This study describes Pyrosequencing assays for key SNPs in CYP3A4 (CYP3A4*1B, CYP3A4*2, and CYP3A4*3) and CYP3A5 (CYP3A5*3C and ...
McLeod Howard L +2 more
openaire +3 more sources
Relevance of genetic polymorphisms of the human cytochrome P450 3A4 in rivaroxaban-treated patients [PDF]
Cellular, Molecular and Biomedical Reports, 2021 Rivaroxaban is an anticoagulant drug that prevents forming of blood clots. In addition, it can be administered to prevent and treat thrombotic diseases such as atrial fibrillation, cardiac arrhythmia, heart valve disease, orthopedic surgery, and ...
Muhammed Ercisli +5 more
doaj +1 more source
CYP3A4 mutation causes vitamin D–dependent rickets type 3
Journal of Clinical Investigation, 2018 Genetic forms of vitamin D–dependent rickets (VDDRs) are due to mutations impairing activation of vitamin D or decreasing vitamin D receptor responsiveness.
Jeffrey D. Roizen +11 more
semanticscholar +1 more source
CYP3A4 Inhibitors Isolated from Licorice
Biological and Pharmaceutical Bulletin, 2005 The extract of licorice (Glycyrrhiza uralensis FISHER, Leguminosae) showed CYP3A4 inhibitory activity with the IC50 value of 0.022 mg/ml. Bioassay-guided purification afforded nine compounds, 3-(p-hydroxyphenyl)propionic acid (1), isoliquiritigenin (2), (3R)-vestitol (3), licopyranocoumarin (4), 4-hydroxyguaiacol apioglucoside (5), liquiritin (6 ...
Sachiko, Tsukamoto +5 more
openaire +3 more sources
Медицинский совет, 2021 Introduction. Apixaban is a direct oral anticoagulant prescribed for treatment and prevention of venous thromboembolism (VTE) and for prevention of stroke in patients with nonvalvular atrial fibrillation.
I. N. Sychev +12 more
doaj +1 more source
Induced fit for cytochrome P450 3A4 based on molecular dynamics
ADMET and DMPK, 2019 The present study aims at numerically describing to what extent substrate - enzyme complexes in solution may change over time as a natural process of conformational changes for a liganded enzyme in comparison to those movements which occur independently ...
Thomas R.F. Scior, Israel Quiroga
doaj +1 more source